Novo Nordisk A/S scrapped a partnership with Hims & Hers Health Inc., saying the US company is using “deceptive marketing” to sell copycat versions of its obesity blockbuster Wegovy. Hims, a telehealth platform,

Novo Nordisk is ending a deal with telehealth company Hims & Hers, saying Monday that Hims has been engaging in “illegal mass compounding” of GLP-1 obesity treatments and “deceptive marketing.”

Novo Nordisk said on Monday it would halt its collaboration with U.S. telehealth company Hims & Hers Health over the distribution of the Danish company's blockbuster Wegovy weight loss drugs. The two companies had announced a collaboration in April for Hims & Hers to sell Wegovy through a bundled offering on the telehealth company's platform.